306 related articles for article (PubMed ID: 35874312)
1. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.
von Scholten BJ; Kreiner FF; Rasmussen S; Rossing P; Idorn T
Ther Adv Endocrinol Metab; 2022; 13():20420188221112490. PubMed ID: 35874312
[TBL] [Abstract][Full Text] [Related]
2. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
3. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.
Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A
Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
[TBL] [Abstract][Full Text] [Related]
10. Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease.
Neumiller JJ; Alicic RZ; Tuttle KR
Clin Kidney J; 2024 Jan; 17(1):sfad285. PubMed ID: 38213492
[TBL] [Abstract][Full Text] [Related]
11. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
Shubrook JH; Neumiller JJ; Wright E
Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311
[TBL] [Abstract][Full Text] [Related]
12. Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease.
Rroji M; Spasovski G
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540270
[TBL] [Abstract][Full Text] [Related]
13. Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.
Mosenzon O; Schechter M; Leibowitz G
Adv Chronic Kidney Dis; 2021 Jul; 28(4):347-360. PubMed ID: 34922691
[TBL] [Abstract][Full Text] [Related]
14. Diabetic kidney disease treatment: new perspectives.
Tong LL; Adler SG
Kidney Res Clin Pract; 2022 Sep; 41(Suppl 2):S63-S73. PubMed ID: 36239062
[TBL] [Abstract][Full Text] [Related]
15. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
Mende CW
Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
[TBL] [Abstract][Full Text] [Related]
16. Progress in the management of patients with diabetes and chronic kidney disease.
Pozo Garcia L; Thomas SS; Rajesh H; Navaneethan SD
Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):456-463. PubMed ID: 35894280
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists.
Górriz JL; Soler MJ; Navarro-González JF; García-Carro C; Puchades MJ; D'Marco L; Martínez Castelao A; Fernández-Fernández B; Ortiz A; Górriz-Zambrano C; Navarro-Pérez J; Gorgojo-Martinez JJ
J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32235471
[TBL] [Abstract][Full Text] [Related]
18. The potential of glucagon-like peptide-1 receptor agonists in heart failure.
Kreiner FF; Hovingh GKK; von Scholten BJ
Front Physiol; 2022; 13():983961. PubMed ID: 36203939
[TBL] [Abstract][Full Text] [Related]
19. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
20. Advancements in diabetic kidney disease management: integrating innovative therapies and targeted drug development.
Ghose S; Satariano M; Korada S; Cahill T; Shah R; Raina R
Am J Physiol Endocrinol Metab; 2024 Jun; 326(6):E791-E806. PubMed ID: 38630049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
